V-Ensure Pharma Raises INR 130 Crore

The round was led by Investcorp along with participation from Asia-based private investment firm, Tanas Capital

By Shrabona Ghosh | Feb 22, 2022
Pexels

Opinions expressed by Entrepreneur contributors are their own.

You're reading Entrepreneur India, an international franchise of Entrepreneur Media.

Investcorp, a global alternative investment firm, on Tuesday invested in V-Ensure Pharma Technologies in a transaction valued at INR 130 crore. The round was led by Investcorp along with participation from Asia-based private investment firm, Tanas Capital.

This investment will fund V-Ensure’s objective of pursuing growth opportunities across North America, Europe and other global markets for the development and launch of its products. The investment also reinforces Investcorp’s commitment to invest in market-leading business services, information technology and healthcare businesses in India and accelerate their expansion and competitive positioning globally, said a statement.

“As our first pharmaceutical deal in India, we are confident that healthcare globally will continue to be center stage for the future. V- Ensure is a renowned name among India-based pharmaceutical research organizations which aims to tap global markets with its own products. Investcorp’s global presence and knowledge will potentially help V-Ensure as they look to establish their presence directly in the US market. We look forward to this partnership and supporting the company in scaling its operations, both in India and globally, drawing upon our global mid-market expertise,” said Gaurav Sharma, head of private equity ofInvestcorp India.

“We are delighted to partner with Investcorp as we expand our business from a CRO to a fully integrated specialty pharmaceutical company. We will continue to deliver patient centric solutions through our proprietary technology and competence in developing complex generics for regulated markets. With the backing of Investcorp’s experienced team and global network, we believe that we will be well positioned to significantly accelerate our growth. I look forward to a successful partnership with Investcorp,” saidSatyanarayana Vemula, CEO of V-Ensure.

Investcorp has been active in the mid-market private equity space in India since 2019, investing across the healthcare, business services, financial services, consumer and retail, and technology sectors, said a statement.

Investcorp, a global alternative investment firm, on Tuesday invested in V-Ensure Pharma Technologies in a transaction valued at INR 130 crore. The round was led by Investcorp along with participation from Asia-based private investment firm, Tanas Capital.

This investment will fund V-Ensure’s objective of pursuing growth opportunities across North America, Europe and other global markets for the development and launch of its products. The investment also reinforces Investcorp’s commitment to invest in market-leading business services, information technology and healthcare businesses in India and accelerate their expansion and competitive positioning globally, said a statement.

“As our first pharmaceutical deal in India, we are confident that healthcare globally will continue to be center stage for the future. V- Ensure is a renowned name among India-based pharmaceutical research organizations which aims to tap global markets with its own products. Investcorp’s global presence and knowledge will potentially help V-Ensure as they look to establish their presence directly in the US market. We look forward to this partnership and supporting the company in scaling its operations, both in India and globally, drawing upon our global mid-market expertise,” said Gaurav Sharma, head of private equity ofInvestcorp India.

Shrabona Ghosh

Senior Correspondent
I write on corporates and lead a project called 'Corporate Innovations', wherein I cover large enterprises across technology, auto, FMCG and avaition. I engage in CEO dialogues and run my podcast series: The Big Bosses. You can reach out to me at gshrabona@entrepreneurindia.com

Related Content

Finance

What Tech-Led IPOs Mean for Retail and Institutional Investors

Global and domestic institutions increasingly treat consumer-tech IPOs as part of their long-duration growth bucket, comparable to specialty retail or branded consumer platforms rather than traditional loss-making tech ventures. Retail investors, however, are engaging with offerings such as this in a structurally different risk environment.